Table 4.

Univariable and multivariable analysis of adverse pregnancy outcomes among women with severe pregnancy-associated hypertension by presence or absence of abnormal laboratory values

	III (n=861)	IV (n=113)
		OR (95%CI)	aOR (95%CI)*
Composite neonatal morbidity†	1 (referent)	2.1 (1.1,3.8)	2.5 (1.3,4.9)++
PTB < 37 weeks	1 (referent)	2.0 (1.3,3.1)++	2.2 (1.4,3.4)+
PTB < 32 weeks	1 (referent)	4.3 (2.0,9.2)+	6.1 (2.7,14.0)+
Indicated PTB < 37 weeks	1 (referent)	2.2 (1.4,3.4)+	2.4 (1.5,3.8)+
Indicated PTB < 32 weeks	1 (referent)	5.1 (2.3,11.0)+	6.7 (2.9,15.8)+
Placental Abruption	1 (referent)	0.85 (0.02,6.2)	**
Fetal or neonatal death (≥20 weeks)	1 (referent)	3.1 (0.3,19.3)	**
SGA (<5th%)	1 (referent)	1.1 (0.6,2.2)	1.1 (0.5,2.2)
NICU Admission	1 (referent)	1.9 (1.2,2.9)++	2.0 (1.3,3.2)++

III, Severe hypertension alone or any hypertension with severe clinical signs; IV, Severe hypertension alone or any hypertension with severe clinical signs + abnormal laboratory values. Boldface indicates p-value <0.05.

^*Adjusted for maternal age, race, baseline BMI, smoking, treatment group (Vitamin C and E or placebo), education level, & family history of preeclampsia

^†RDS, Sepsis, NEC, IVH (Grade III or IV), ROP, Apgar ≤3 at 5 min

^**Numbers too small to calculate adjusted OR

⁺Indicates p-value <0.001

⁺⁺Indicates p-value <0.01